Encoded Therapeutics key facts
as of Oct 2026- Encoded Therapeutics is valued at approximately $1.8B as of Oct 2026, set at its Series F, Sep 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $275.0M across 2 recorded rounds; the latest was Series F ($275.0M) in Sep 2026.
- Notable investors include ARCH Venture Partners, Venrock, Illumina Ventures, RTW Investments, Farallon Capital Management — 9 tracked in total.
Valued at $1.8B at its Series F, Sep 2026. Nothing has traded since.
- ·The post-money valuation on its round
- ·Watch Encoded Therapeutics: the Monday email on marks, rounds and moves
Encoded Therapeutics funding rounds
2 roundsEncoded Therapeutics valuation
Encoded Therapeutics was valued at $1.8 billion at its Series F in Sep 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
Recent activity
In the last 90 days, Encoded Therapeutics's record added 1 funding round.
How much has Encoded Therapeutics raised?
Encoded Therapeutics has raised $275 million across 2 recorded rounds since 2017. The largest was a $275 million Series F in Sep 2026. 1 of the rounds disclosed a post-money valuation.
Encoded Therapeutics investors
9 investors are on record for Encoded Therapeutics, including ARCH Venture Partners, Venrock, Illumina Ventures and RTW Investments. By type, the record holds 4 venture capital firms, 4 hedge funds and 1 family office. The Series F in Sep 2026 drew 12 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Formation Bio ($1.7 billion), Areteia Therapeutics ($1.3 billion) and Neurona Therapeutics ($1.1 billion).
About Encoded Therapeutics
- Industry
- Drug Discovery
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.